Our African Malaria Partnership was established in 2001. It works with NGOs to educate communities about malaria and the preventative measures that can be taken against it, such as sleeping under treated bed nets and seeking immediate treatment for children showing signs of fever.
A vaccine against malaria?
For three decades, GSK and its partners have been developing what could be the world’s first vaccine to help protect children in Africa against malaria.
Our vaccine candidate RTS,S, also known as MosquirixTM, has been developed in partnership with PATH MVI, supported by grants from the Bill & Melinda Gates Foundation.
Finding ways to overcome the malaria parasite’s defence mechanisms is extraordinarily challenging. But we are now a step closer to fulfilling that goal.
In July 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use granted RTS,S a positive scientific opinion.
The World Health Organization has indicated that a policy recommendation for the vaccine candidate could be possible by the end of 2015. GSK would then apply for a WHO ‘pre-qualification’, before applying for marketing authorisation in sub-Saharan African countries. These decisions would, if successful, pave the way toward implementation of RTS,S through African immunisation programmes. If approved, RTS,S is intended to complement existing measures to fight malaria, such as bed nets and indoor residual insecticide spraying.
GSK, MVI, and other partners are working to do what they can to ensure that RTS,S – if approved for use – reaches the infants and children who need it most. GSK has committed the eventual price will cover the cost of manufacturing the vaccine together with a small return of around 5% that will be reinvested in research and development for second-generation malaria vaccines, or vaccines against other neglected tropical diseases.